Recent advances in the genetic neuropathies

Current Opinion in Neurology

Volumn 29, Issue 5, 2016, Pages 537-548

  Rossor, Alexander M ^a   Tomaselli, Pedro J ^a   Reilly, Mary M ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Charcot Marie Tooth disease; Hereditary motor and sensory neuropathy; Hereditary motor neuropathy; Hereditary sensory neuropathy; Treatment

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCINE TRANSFER RNA LIGASE; NRP1 RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

CLINICAL TRIAL (TOPIC); CMT1A GENE; CMT1B GENE; DISEASE COURSE; GENE; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE TARGETING; GENETIC IDENTIFICATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MOLECULAR DIAGNOSIS; MOLECULAR MECHANICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHENOTYPE; RATIONAL EMOTIVE BEHAVIOR THERAPY; REVIEW; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; ANIMAL; GENETICS; MUTATION; PERIPHERAL NEUROPATHY;

ANIMALS; CHARCOT-MARIE-TOOTH DISEASE; HUMANS; MUTATION; PERIPHERAL NERVOUS SYSTEM DISEASES; SIGNAL TRANSDUCTION;

EID: 84986224293     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000373     Document Type: Review

References (46)

1. Rossor AM, Evans MRB, Reilly MM. A practical approach to the genetic neuropathies. Pract Neurol 2015; 15:187-198.
2. Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 2013; 9:562-571.
3. Gonzaga-Jauregui C, Harel T, Gambin T, et al. Exome sequence analysis suggests that genetic burden contributes to phenotypic variability and complex neuropathy. Cell Rep 2015; 12:1169-1183.
4. Lupo V, García-García F, Sancho P, et al. Assessment of targeted next-generation sequencing as a tool for the diagnosis of Charcot-Marie-Tooth disease and hereditary motor neuropathy. J Mol Diagn 2016; 18:225-234.
5. Nam SH, Hong Y Bin. Hyun YS, et al. Identification of genetic causes of inherited peripheral neuropathies by targeted gene panel sequencing. Mol Cells 2016; 39:382-388.
6. Jo H-Y, Park M-H, Woo H-M, et al. Application of whole-exome sequencing for detecting copy number variants in CMT1A/HNPP. Clin Genet 2016; 90:177-181.
7. Rudnik-Schöneborn S, Tölle D, Senderek J, et al. Diagnostic algorithms in Charcot-Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis of 1206 index patients. Clin Genet 2016; 89: 34-43.
8. Murphy SM, Laura M, Fawcett K, et al. Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry 2012; 83:706-710.
9. Hong YB, Joo J, Hyun YS, et al. A mutation in PMP2 causes dominant demyelinating Charcot-Marie-Tooth neuropathy. PLoS Genet 2016; 12:e1005829.
10. Motley WW, Palaima P, Yum SW, et al. De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease. Brain 2016; 139: 1649-1656.
11. Zenker J, Stettner M, Ruskamo S, et al. A role of peripheral myelin protein 2 in lipid homeostasis of myelinating Schwann cells. Glia 2014; 62:1502-1512.
12. Sevilla T, Lupo V, Martínez-Rubio D, et al. Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease. Brain 2016; 139:62-72.
13. Albulym OM, Kennerson ML, Harms MB, et al. MORC2 mutations cause axonal Charcot-Marie-Tooth disease with pyramidal signs. Ann Neurol 2015; 79:419-427.
14. Higuchi Y, Hashiguchi A, Yuan J, et al. Mutations in MME cause an autosomalrecessive Charcot-Marie-Tooth disease type 2. Ann Neurol 2016; 79:659-672.
15. Rebelo AP, Abrams AJ, Cottenie E, et al. Cryptic amyloidogenic elements in the 30 UTRs of neurofilament genes trigger axonal neuropathy. Am J Hum Genet 2016; 98:597-614.
16. Brennan KM, Bai Y, Pisciotta C, et al. Absence of dystrophin related protein-2 disrupts Cajal bands in a patient with Charcot-Marie-Tooth disease. Neuromuscul Disord 2015; 25:786-793.
17. Hong YB, Kang J, Kim JH, et al. DGAT2 mutation in a family with autosomal dominant early-onset axonal Charcot-Marie-Tooth disease. Hum Mutat 2016; 37:473-480.
18. Té treault M, Gonzalez M, Dicaire M-J, et al. Adult-onset painful axonal polyneuropathy caused by a dominant NAGLU mutation. Brain 2015; 138:1477-1483.
19. Montecchiani C, Pedace L, Lo Giudice T, et al. ALS5/SPG11/KIAA1840 mutations cause autosomal recessive axonal Charcot-Marie-Tooth disease. Brain 2016; 139:73-85.
20. Nguyen TP, Biliciler S, Wiszniewski W, Sheikh K. Expanding phenotype of VRK1 mutations in motor neuron disease. J Clin Neuromuscul Dis 2015; 17:69-71.
21. Sereda MW, Meyer ZU, Hörste G, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003; 9:1533-1537.
22. Gess B, Baets J, De Jonghe P, et al. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease. Cochrane Database Syst Rev 2015; 12:CD011952.
23. Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005; 65:681-689.
24. Sahenk Z, GallowayG, Clark KR, et al. AAV1.NT-3 gene therapy for Charcot-Marie-Tooth neuropathy. Mol Ther 2014; 22:511-521.
25. Fledrich R, Stassart RM, Klink A, et al. Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nat Med 2014; 20:1055-1061.
26. Martini R. Neuregulin-1 alleviates Charcot-Marie-Tooth disease in rats. Nat Med 2014; 20:984-985.
27. Lee SM, Chin L-S, Li L. Dysregulation of ErbB receptor trafficking and signaling in demyelinating Charcot-Marie-Tooth disease. Mol Neurobiol 2016. [Epub ahead of print]
28. Klein D, Patzkó Á , Schreiber D, et al. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice. Brain 2015; 138:3193-3205.
29. Attarian S, Vallat J-M, Magy L, et al. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis 2014; 9:199.
30. Chumakov I, Milet A, Cholet N, et al. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J Rare Dis 2014; 9:201.
31. Bai Y, Patzko A, Shy ME. Unfolded protein response, treatment and CMT1B. Rare Dis (Austin, TX) 2013; 1:e24049.
32. Das I, Krzyzosiak A, Schneider K, et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science 2015; 348:239-242.
33. Misko AL, Sasaki Y, Tuck E, et al. Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration. J Neurosci 2012; 32:4145-4155.
34. He W, Zhang H-M, Chong YE, et al. Dispersed disease-causing neomorphic mutations on a single protein promote the same localized conformational opening. Proc Natl Acad Sci U S A 2011; 108:12307-12312.
35. He W, Bai G, Zhou H, et al. CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase. Nature 2015; 526:710-714.
36. Spaulding EL, Sleigh JN, Morelli KH, et al. Synaptic deficits at neuromuscular junctions in two mouse models of Charcot-Marie-Tooth type 2d. J Neurosci 2016; 36:3254-3267.
37. d'Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011; 17:968-974.
38. Shen S, Benoy V, Bergman JA, et al. Bicyclic-capped histone deacetylase 6 inhibitors with improved activity in a model of axonal Charcot-Marie-Tooth disease. ACS Chem Neurosci 2016; 7:240-258.
39. Kagiava A, Sargiannidou I, Theophilidis G, et al. Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy. Proc Natl Acad Sci U S A 2016; 113:E2421-E2429.
40. Sargiannidou I, Kagiava A, Bashiardes S, et al. IntraneuralGJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease. Ann Neurol 2015; 78:303-316.
41. Deyle DR, Russell DW. Adeno-associated virus vector integration. Curr Opin Mol Ther 2009; 11:442-447.
42. Cornett KM, Menezes MP, Bray P, et al. Phenotypic variability of childhood Charcot-Marie-Tooth disease. JAMA Neurol 2016; 73:645-651.
43. Sanmaneechai O, Feely S, Scherer SS, et al. Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene. Brain 2015; 138:3180-3192.
44. Sadjadi R, Reilly MM, Shy ME, et al. Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis. J Peripher Nerv Syst 2014; 19:192-196.
45. Piscosquito G, Reilly MM, Schenone A, et al. Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease. Eur J Neurol 2015; 22:1556-1563.
46. Morrow JM, Sinclair CDJ, Fischmann A, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol 2016; 15:65-77.